Endo Makes First M&A Move Under New Regime, Building In Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma will acquire generic drug maker Boca Pharmacal for $225 million, following through on new CEO De Silva’s plans to reshape the company through M&A.